Evaluation of the safety and effectiveness of Haploidentical hematopoietic stem cell transplantation for the treatment of severe aplastic anemia patients who lack an Human leukocyte antigen (HLA)-matched (sibling or unrelated) donor.

Tehran University of Medical Sciences0 sites10 target enrollmentTBD

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Not specified
Sponsor: Tehran University of Medical Sciences
Enrollment: 10
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

last year

Study Type

Interventional

Sex

All

Investigators

Sponsor

Tehran University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

•Patients from 18 to 60 years old
•Patients with Severe Aplastic Anemia
•Patients unresponsive to prior immune suppressive treatments.
•No full matched (sibling or unrelated) donor available.

Exclusion Criteria

•Prior allogeneic stem cell transplantation
•Symptomatic coronary artery disease
•Karnofsky Performance Score \< 60
•Patients with uncontrolled bacterial, viral or fungal infection
•A known life\-threatening reaction (anaphylaxis) to Thymoglobin.
•Females who are pregnant or breastfeeding.
•Patients seropositive for human immunodeficiency virus or active hepatitis B or C with detectable viral load.
•Received Antithymocyte globulin drug within 2 weeks before enrolling in the study.
•Previous malignancies other than resected basal cell carcinoma or cervical cancer treated in situ.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting

Phase 2

To Study the effects of Unani formulation Habb e Mujarrab in patients with Migraine without auraHealth Condition 1: G430- Migraine without aura

CTRI/2023/03/050748Central Council for Research in Unani Medicine New Delhi

Recruiting

Not Applicable

Assessment of the safety and performance of the HARPOON* Beating Heart Mitral Valve Repair System; a multi-center post-market study (The ASCEND Study).

NL-OMON50870HARPOON Medical, an indirect wholly-owned subsidiary of Edwards Lifesciences Corporation20

Active, not recruiting

Not Applicable

Assessment of the Safety and Performance of the HARPOON™ Beating Heart Mitral Valve Repair System; a Multi-center Post-market Study (ASCEND)Severe Degenerative Mitral Regurgitation due to Mid-segment Posterior Leaflet Prolapse

DRKS00022786Harpoon Medical, an indirect-wholly owned subsidiary of Edwards Lifesciences Corporation, Edwards Lifesciences,42

Completed

Phase 3

Clinical trial of â??AHPL/AYTOP/2014Aâ?? Gel in mouth ulcer

CTRI/2017/04/008386Ari Healthcare Pvt Ltd

Recruiting

Phase 1

k cell therapy for recurrent GBM (Glioblastoma Multiform)Recurrent Glioblastoma Multiform(GBM) and resistant/recurrent malignant brain tumor.Malignant neoplasm of brain, unspecifiedC71.9

IRCT20170122032121N5Iranian academic center for education culture and research5